Lifeward Ltd. (LFWD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $11.53M
Last updated: Nov 17, 2026 at 10:42 AM ET
Lifeward Ltd. (LFWD) Earnings: Report Dates and Results
Lifeward (LFWD) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Lifeward reported EPS of -$1.32, below the -$0.53 estimate. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LFWD has an expected report date of Mar 16, 2027.
LFWD Earnings Call
The latest LFWD earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 39 quarters below that had an estimate, LFWD beat 14, missed 23 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $5.43M, down 12.4% from $6.20M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.32 | -$0.53 | N/A | -149.06% | Miss | N/A | 1 | 0 up, 0 down | Nov 13, 2026 | $5.43M |
| Jun 30, 2026 | -$1.46 | -$1.49 | N/A | +2.01% | Beat | N/A | 1 | 0 up, 0 down | Aug 14, 2026 | $6.62M |
| Mar 31, 2026 | -$6.70 | -$0.34 | -$0.34 - -$0.34 | N/A | N/A | N/A | 1 | 1 up, 0 down | May 15, 2026 | $3.92M |
| Dec 31, 2025 | -$2.85 | -$1.08 | -$1.08 - -$1.08 | -163.89% | Miss | N/A | 1 | 0 up, 0 down | Mar 18, 2026 | $5.08M |
| Sep 30, 2025 | -$2.28 | -$1.92 | N/A | -18.75% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2025 | $6.20M |
| Jun 30, 2025 | -$3.72 | -$2.88 | -$2.88 - -$2.88 | -29.17% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2025 | $5.72M |
| Mar 31, 2025 | -$0.46 | -$0.33 | -$0.33 - -$0.24 | -39.39% | Miss | N/A | 2 | 0 up, 0 down | May 15, 2025 | $5.03M |
| Dec 31, 2024 | -$0.38 | -$0.33 | -$0.33 - -$0.33 | -15.15% | Miss | N/A | 1 | 1 up, 0 down | Mar 7, 2025 | $7.54M |
| Sep 30, 2024 | -$4.20 | -$3.78 | -$4.32 - -$3.24 | -11.11% | Miss | N/A | 2 | 2 up, 0 down | Nov 12, 2024 | $6.13M |
| Jun 30, 2024 | -$6.00 | -$6.60 | N/A | +9.09% | Beat | N/A | N/A | N/A | Aug 14, 2024 | $6.71M |
| Mar 31, 2024 | -$7.44 | -$8.40 | N/A | +11.43% | Beat | N/A | N/A | N/A | May 15, 2024 | $5.28M |
| Dec 31, 2023 | -$4.20 | -$9.24 | N/A | +54.55% | Beat | N/A | N/A | N/A | Feb 27, 2024 | $6.88M |
| Sep 30, 2023 | -$6.72 | -$8.40 | N/A | +20.00% | Beat | N/A | N/A | N/A | Nov 14, 2023 | $4.40M |
| Jun 30, 2023 | -$5.29 | -$5.88 | N/A | +10.03% | Beat | N/A | N/A | N/A | Aug 11, 2023 | $1.34M |
| Mar 31, 2023 | -$5.67 | -$6.72 | N/A | +15.63% | Beat | N/A | N/A | N/A | May 11, 2023 | $1.23M |
| Dec 31, 2022 | -$7.56 | -$5.88 | N/A | -28.57% | Miss | N/A | N/A | N/A | Feb 23, 2023 | $2.18M |
| Sep 30, 2022 | -$7.56 | -$5.04 | N/A | -50.00% | Miss | N/A | N/A | N/A | Nov 7, 2022 | $886000 |
| Jun 30, 2022 | -$5.88 | -$3.36 | N/A | -75.00% | Miss | N/A | N/A | N/A | Aug 9, 2022 | $1.57M |
| Mar 31, 2022 | -$5.57 | -$4.20 | N/A | -32.62% | Miss | N/A | N/A | N/A | May 13, 2022 | $876000 |
| Dec 31, 2021 | -$5.04 | -$3.36 | N/A | -50.00% | Miss | N/A | N/A | N/A | Feb 24, 2022 | $1.24M |
| Sep 30, 2021 | -$5.04 | -$5.04 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 10, 2021 | $1.97M |
| Jun 30, 2021 | -$5.88 | -$5.04 | N/A | -16.67% | Miss | N/A | N/A | N/A | Aug 9, 2021 | $1.44M |
| Mar 31, 2021 | -$6.55 | -$5.88 | N/A | -11.39% | Miss | N/A | N/A | N/A | May 11, 2021 | $1.32M |
| Dec 31, 2020 | -$11.76 | -$11.76 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 18, 2021 | $1.22M |
| Sep 30, 2020 | -$15.12 | -$13.44 | N/A | -12.50% | Miss | N/A | N/A | N/A | Nov 10, 2020 | $747000 |
| Jun 30, 2020 | -$18.48 | -$22.68 | N/A | +18.52% | Beat | N/A | N/A | N/A | Aug 12, 2020 | $1.67M |
| Mar 31, 2020 | -$2.59 | -$0.26 | N/A | -896.15% | Miss | N/A | N/A | N/A | May 28, 2020 | $760000 |
| Dec 31, 2019 | -$41.16 | -$30.24 | N/A | -36.11% | Miss | N/A | N/A | N/A | Feb 20, 2020 | $1.18M |
| Sep 30, 2019 | -$38.64 | -$37.80 | N/A | -2.22% | Miss | N/A | N/A | N/A | Nov 13, 2019 | $1.23M |
| Jun 30, 2019 | -$73.92 | -$41.16 | N/A | -79.59% | Miss | N/A | N/A | N/A | Aug 8, 2019 | $877000 |
| Mar 31, 2019 | -$105.00 | -$84.00 | N/A | -25.00% | Miss | N/A | N/A | N/A | May 7, 2019 | $1.58M |
| Dec 31, 2018 | -$210.00 | -$294.00 | N/A | +28.57% | Beat | N/A | N/A | N/A | Feb 8, 2019 | $1.58M |
| Sep 30, 2018 | -$273.00 | -$294.00 | N/A | +7.14% | Beat | N/A | N/A | N/A | Nov 8, 2018 | $1.62M |
| Jun 30, 2018 | -$378.00 | -$336.00 | N/A | -12.50% | Miss | N/A | N/A | N/A | Aug 14, 2018 | $1.77M |
| Mar 31, 2018 | -$36.75 | -$38.49 | N/A | +4.52% | Beat | N/A | N/A | N/A | May 10, 2018 | $1.58M |
| Dec 31, 2017 | -$422.73 | -$546.00 | N/A | +22.58% | Beat | N/A | N/A | N/A | Mar 8, 2018 | $1.51M |
| Sep 30, 2017 | -$462.21 | -$735.00 | N/A | +37.11% | Beat | N/A | N/A | N/A | Nov 2, 2017 | $1.73M |
| Jun 30, 2017 | -$602.39 | -$805.00 | N/A | +25.17% | Beat | N/A | N/A | N/A | Aug 3, 2017 | $2.01M |
| Mar 31, 2017 | -$68.25 | -$10.08 | N/A | -577.08% | Miss | N/A | N/A | N/A | May 4, 2017 | $2.50M |
| Dec 31, 2016 | -$997.29 | -$934.50 | N/A | -6.72% | Miss | N/A | N/A | N/A | Feb 17, 2017 | $1.59M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$9.31, after -$18.02 the year before. It was -$4,443.41 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$9.31 | N/A |
| Dec 31, 2024 | -$18.02 | N/A |
| Dec 31, 2023 | -$21.88 | N/A |
| Dec 31, 2022 | -$26.57 | N/A |
| Dec 31, 2021 | -$22.51 | N/A |
| Dec 31, 2020 | -$47.95 | N/A |
| Dec 31, 2019 | -$258.72 | N/A |
| Dec 31, 2018 | -$897.75 | N/A |
| Dec 31, 2017 | -$1,555.58 | N/A |
| Dec 31, 2016 | -$4,443.41 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,800 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 2,767 | 5 | |
| 2025Q3 | Sep 30, 2025 | 3,977 | 5 | |
| 2025Q2 | Jun 30, 2025 | 5,539 | 6 | |
| 2025Q1 | Mar 31, 2025 | 5,658 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,898 | 6 | |
| 2024Q3 | Sep 30, 2024 | 5,644 | 6 | |
| 2024Q2 | Jun 30, 2024 | 4,139 | 5 |
2026Q1 Earnings Call
Opening remarks
Almog Adar CFO Thank you, Drew, and thanks, everyone, who has joined us on the call today. My name is Almog Adar, I'm Lifeward's Chief Financial Officer. And with me on today's call is our President and Chief Executive Officer, Mark Grant. Earlier this morning, Lifeward issued a press release detailing the financial results for the first quarter ended March 31, 2026. I would ask you to review the full text of our forward-looking statements from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. With that, I will turn the call over to Mark.
Mark Grant President & Chief Executive Officer Thank you, Almog, and thank you for everybody for joining us today. The first quarter of 2026 marked an important strategic milestone for Lifeward as we successfully completed the acquisition of Oratech. We believe this transaction significantly strengthens Lifeward's position as a diversified biomedical innovation company while reinforcing our focus on neurorehabilitation and our path toward profitability. We believe this was a highly strategic and capital-efficient transaction for Lifeward shareholders. Through the equity-based acquisition of Oratech, we gained access to the protein oral delivery platform, a potentially transformative technology across many therapeutic indications, including ORMD-0801 oral insulin, which is expected to commence a Phase II study. Importantly, the clinical program management responsibilities remain with Oramed, utilizing funds previously transferred to Oratech as part of the strategic transaction. That means Lifeward and our shareholders by owning the protein orally delivered platform outright effectively receive a meaningful option on the potential success of the promising technology with minimal near-term operational burden, no material increase in operating expenses and limited management bandwidth requirements beyond my own involvement, supporting strategic oversight and development guidance. As many of you know, my background includes extensive experience in diabetes and metabolic disease, and I believe this platform has meaningful long-term potential. At the same time, Lifeward's core focus remains firmly centered on scaling our neurorehabilitation MedTech business. The second key takeaway from the quarter is Lifeward is now substantially better positioned on its path to profitability. With the $10 million from our convertible note financing, we have significantly strengthened our balance sheet and improved our operating flexibility. This allows us to stabilize and build upon the fundamental and foundational work we have done over the last several quarters, while maintaining our disciplined focus on operational efficiency, market access and innovation across our neurorehabilitation platform. We expect continued operational stabilization over the next several quarters as our baseline resets following our manufacturing transition initiatives completed over the last year and the consummation of the important transaction this quarter.
Frequently Asked Questions About LFWD
When is Lifeward's next earnings date?
Lifeward's next earnings report is expected for Mar 16, 2027.
Did LFWD beat earnings estimates last quarter?
No. Lifeward reported EPS of -$1.32 for the quarter ended Sep 30, 2026, below the -$0.53 estimate by 149.06%.
What EPS do analysts expect from LFWD next quarter?
The consensus EPS estimate for Lifeward for the quarter ending Dec 31, 2026 is -$0.71 from 4 analysts, with estimates from -$0.81 to -$0.60.
How often does LFWD beat earnings estimates?
Lifeward beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -53.06%.
LFWD pages: Overview, Earnings, Forecast, Financials, Competitors